Who Paid My Doc
John Bird
Pediatric Allergy/Immunology Dallas, TX Medical Doctor
NPI 1851592752 CMS profile 266387
5323 Harry Hines Blvd, Dallas, TX 75390
General payments
$35,867
Research payments
$1,214
Ownership & investment interest
$0
Research they led as principal investigator
$371,373
Through program year 2025, John Bird of Dallas, TX is reported in the CMS Open Payments database as having received $35,867 across 68 general payments and $1,214 in research payments paid to them. Separately, studies naming them as principal investigator received $371,373 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 87th percentile of Pediatric Allergy/Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
8 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $7,229 | 15 | |
| 2024 | General | $5,969 | 9 | |
| 2023 | General | $5,406 | 4 | |
| 2023 | Research | $1,214 | 1 | |
| 2022 | General | $7,321 | 15 | |
| 2021 | General | $4,542 | 6 | |
| 2020 | General | $5,222 | 14 | |
| 2019 | General | $180 | 5 |
Beside peers
- John Bird
- Pediatric Allergy/Immunology median
- Middle half of Pediatric Allergy/Immunology
- National median
In program year 2025, general payments to John Bird were reported at $7,229. Among 289 Pediatric Allergy/Immunology profiles paid that year, the median was $361 and the middle half received between $125 and $2,493.
Show as a table
| Year | John Bird | Pediatric Allergy/Immunology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $180 | $325 | $92–$1,399 | $163 |
| 2020 | $5,222 | $144 | $66–$2,490 | $114 |
| 2021 | $4,542 | $357 | $95–$2,633 | $132 |
| 2022 | $7,321 | $385 | $125–$2,259 | $149 |
| 2023 | $5,406 | $470 | $121–$2,946 | $160 |
| 2024 | $5,969 | $317 | $125–$2,583 | $164 |
| 2025 | $7,229 | $361 | $125–$2,493 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
69 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Pediatric Allergy/Immunology in Texas
Lisa Satter
Pediatric Allergy/Immunology · Houston, TX
Niti Chokshi
Pediatric Allergy/Immunology · Houston, TX
Imelda Hanson
Pediatric Allergy/Immunology · Houston, TX
Aikaterini Anagnostou
Pediatric Allergy/Immunology · Houston, TX
Christopher Parrish
Pediatric Allergy/Immunology · Dallas, TX
Timothy Chow
Pediatric Allergy/Immunology · Dallas, TX
Related records
Pediatric Allergy/Immunology in Texas
Practitioners in the same specialty and state, ranked by reported value.
All Pediatric Allergy/Immunology
Everyone recorded under this specialty, nationwide.
Doctors in Texas
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.